2026 Program

Morning: Inspiration (plenary)

09.00 – 09.30  Doors open and welcome coffee

09.30 – 09.45  Welcome words from Ann Van Gysel (CEO, Biovia)

09.45–10.15  Opening Keynote: From Immunological Insight to Societal Impact: How Co-Creation Transforms Breakthrough Science into Better Lives

Peter Ulrichts (CSO, Argenx)

A personal journey from researcher to CSO, alongside the evolution of argenx from science-driven start-up to global biotech. At the heart of the story is a belief in co-creation: bringing academic insight and industry capabilities together to turn bold science into medicines that can make a meaningful difference for patients.

10.15–10.30  Patient spotlight: Can Belgium Lead the Immunology Revolution?

Fireside chat with Els Van Gysel (Patient) and Ann Van Gysel (CEO, Biovia)

Through one patient’s CAR-T experience, this fireside chat brings the human story behind cell therapy to the stage, from the uncertainty of diagnosis to treatment and life afterwards. It is a timely reminder that every scientific breakthrough ultimately becomes deeply personal, and that the patient voice should remain at the centre of innovation.

10.30–10.55  Making CAR-T Real: From Breakthrough Science to a Therapy for One

Frederik Buysse (General Manager/VP Europe, Legend Biotech)

Scientific discovery only changes lives when it can be translated into a medicine and delivered safely to the patient who needs it. Legend Biotech offers a look behind that journey: building a facility from the ground up, recruiting and qualifying hundreds of people, and managing a highly complex supply chain for a personalised therapy.

10.55–11.25  Networking coffee break and booths & poster presentations

11.25–11.50  Keynote: Multispecific T Cell Engagers: The Next Generation of Cancer Immunotherapy

 Ulrike Philippar (Vice President Oncology, Global Head of Discovery Hematological & Solid Malignancies at Johnson & Johnson Innovative Medicine)

11.50–12.15  Keynote: Computational & AI Drug Design for Antibodies

Rich Taylor (Director CADD Team, UCB)

12.15–12.30  Keynote: From Clinical Research to Patient Access: Making Belgium a Launch Country for Innovation

Patricia van Dijck (Political & Medical Director Pharma.be)

Belgium brings together strong science, clinical expertise and a healthcare ecosystem capable of contributing to the development of innovative therapies.​ Yet new treatments do not always reach Belgian patients or access is delayed. This talk opens a discussion on how Belgium can become a more attractive launch country and translate its strengths into faster and broader patient access.​

12.30–13.30  Networking lunch break and booths & poster presentations

Afternoon breakout sessions

PARALLEL TRACK 1

Auditorium

Immunology Therapies

Track 1 focuses on how immunology is translated into therapies that directly impact patients.

 

It explores clinical applications such as immunotherapies, cancer vaccines and antibody–drug conjugates, with a strong emphasis on clinical outcomes, treatment strategies and real-world challenges in bringing these therapies to patients.

Session Moderator: Karine Breckpot, VUB

13.30–13.45  High-throughput droplet microfluidics for immunotherapy research: From antibody discovery to functional assays and 3D models

Natacha Coppieters (CSO, LiveDrop)

13.45–14.00  From Promise to Practice: Nine years of real-world CAR-T lessons

Bart Jacobs (Cell Therapy Medical Lead BeNeLux, Kite Pharma)

14.00–14.15  mRNA-LNPs encoding disease-relevant autoantigens for attenuated disease in preclinical models of multiple sclerosis and type 1 diabetes

Paulien Baeten (Postdoctoral researcher, Hasselt University), and Karen Beets (Senior Scientist in vitro pharmacology, Etherna)

14.15–14.30  Making Cell and Gene Therapies Happen: Bridging academic innovation, GMP-manufacturing and theATMP ecosystem

Nathalie Cools (Laboratory of Experimental Hematology, University of Antwerp & CEO, Anicells)  ​

14.30–14.45 Clinical development of an mRNA-LNP cancer vaccine in an academic setting

Rein Verbeke, (Senior reseacher, Ghent University)

14.45–15.15  Panel with case study speakers

PARALLEL TRACK 2

Studio 201

Antibody Engineering

Track 2 centres on the scientific and technological foundations that enable next-generation immunotherapies.

It examines how antibodies are designed, engineered and optimised — from molecular architecture and functional enhancement to manufacturability — to create more precise, robust and scalable treatments.

Session Moderator: Eva Lion, University of Antwerp

13.30–13.45  RETROFIT Platform: lab-in-the-loop powered by AI for next-gen immunotherapy.

Abhishek D. Garg (Director & Co-founder, RETROFIT / KU Leuven) and Catherine Hoofd (Business manager, RETROFIT / KU Leuven)

13.45–14.00  In silico Immunogenicity Assessment in Biologics development: From CD4 epitope prediction to clinical ADA risk

Manon Montyne (Principal Data Scientist, myNEO)

14.00–14.15  From Precision to Performance: Why better cancer drug delivery needs more than targeting

Katrien Reynders-Frederix (Founder and CEO, Nanotherix)

14.15–14.30  How smart silicon chip technology can help speed up protein engineering

Chengxun Liu (Technology manager & principle scientist life science, imec)

14.30–14.45  HyperXpress: A paradigm shift in plant-based biomanufacturing of monoclonal antibodies

Jeroen Hofenk (Founder & CSO, SwiftPharma)

14.45–15.15  Panel with case study speakers

15.15–16.00  Coffee break 

Afternoon plenary

16.00–16.30  Keynote: From Belgian Science to a Record-Breaking Series A: The Coultreon Biopharma Success Story

Pierre Raboisson (CEO-CSO and founder, Coultreon Biopharma)

Coultreon Biopharma’s journey is a powerful example of how ambitious Belgian science can attract international confidence and grow into a landmark financing story. The keynote looks beyond the headline to the vision, decisions, partnerships and perseverance behind this milestone, offering an honest success story for the next generation of life sciences entrepreneurs.

16.30–17.15 Interactive Panel: The Cabinets Are Asking. The SME Response.

Pierre Raboisson (CEO-CSO and founder, Coultreon Biopharma), Ann Van Gysel (CEO, Biovia), Tom Aelbrecht (COO J&J Campus Belgium & Head of Strategic Partnerships, Johnson & Johnson), Pierre Vandepapelière (Co founder, CEO  Amyl Therapeutics), Filomeen Haerynck (Pediatric Immunologist, Principal Investigator and Associate Professor, Ghent University & Ghent University Hospital)

Moderated by Vanessa Vankerckhoven (CEO and Co-Founder, IDEVAX)

The cabinets of Matthias Diependaele and Frank Vandenbroucke want to hear directly from SMEs: what pressures are they experiencing in Belgium’s health innovation ecosystem, and which measures do they recommend?
This closing interactive panel will explore what government should do in practical terms, what pharma’s position and future in Belgium mean for smaller companies, and how Belgium should approach competition and collaboration with China.
Participants are invited to contribute their own business experience and help formulate concrete, actionable proposals that Biovia can take back to the cabinets.

17.15–17.30  Closing Words from Viggo Van Tendeloo (Director Early Innovation Partnering Benelux, Johnson & Johnson)

17.30–18.30  Reception

Stay up-to-date
Sign up and we will keep you posted on speakers, program details and open registrations!

Stay up-to-date

Sign up for our newsletter and be the first to receive information on our next edition.

Contact